Myelodysplastic Syndromes
February 2018 Issue

Nearly every major medical breakthrough over the past 50 years can be attributed to new discoveries that were made possible through meticulous biomedical research. Many diseases and conditions that previously took a heavy toll on patients in terms of both morbidity and mortality are now either treatable or preventable thanks in large part to painstaking research that expanded the frontiers of scientific knowledge and moved the most promising basic research developments into tangible health benefits through human clinical trails. Ongoing research is also the key that will open the door to additional major medical advances and breakthroughs in the future.

Our staff at Medifocus is committed to keeping our subscribers to the Medifocus Digest Alert on Myelodysplastic Syndromes abreast of the latest new research developments that have recently been published in the medical literature for this condition. In this issue of the Digest Alert, you will find a focused list of hand-picked journal article references that represent the latest advances in basic and clinical research for Myelodysplastic Syndromes. These articles represent the current state-of-the-art of the research that will hopefully lead to additional major advances and breakthroughs in the clinical management of Myelodysplastic Syndromes. You can access the summaries of each article referenced below by simply clicking on the article Title.

We will continue to update you with the latest scientific and clinical developments through the Medifocus Digest Alert on Myelodysplastic Syndromes every 3 months. Thank you for your ongoing subscription to this publication.

Elliot Jacob, Ph.D.
Vice-President - Content, Inc.

1:Myelodysplastic syndromes: 2018 update on diagnosis, risk-stratification and management.
Authors:Montalban-Bravo G, Garcia-Manero G
Institution:Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, Texas. Texas.
Journal:Am J Hematol. 2018 Jan;93(1):129-147. doi: 10.1002/ajh.24930.

2:Treatment of relapsed AML and MDS after allogeneic stem cell transplantation with decitabine and DLI-a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group.
Authors:Schroeder T, Rautenberg C, Kruger W, Platzbecker U, Bug G, Steinmann J, Klein S, Hopfer O, Nachtkamp K, Kondakci M, Geyh S, Haas R, Germing U, Bornhauser M, Kobbe G
Institution:Department of Hematology, Oncology and Clinical Immunology, Medical Faculty, University of Duesseldorf, Moorenstr. 5, 40225, Dusseldorf, Germany.; Clinic and Policlinic for Internal Medicine C, Hematology and Oncology, University of Greifswald, Greifswald, Germany.; Medical Clinic and Policlinic I, University Hospital Carl Gustav Carus, Dresden, Germany.; Department of Medicine II, University Hospital Frankfurt, Frankfurt am Main, Germany.; Med. Clinic III, University Medicine Mannheim, Mannheim, Germany.
Journal:Ann Hematol. 2018 Feb;97(2):335-342. doi: 10.1007/s00277-017-3185-5. Epub 2017 Nov 18.

3:Impact of baseline cytogenetic findings and cytogenetic response on outcome of high-risk myelodysplastic syndromes and low blast count AML treated with azacitidine.
Authors:Sebert M, Komrokji RS, Sekeres MA, Prebet T, Cluzeau T, Santini V, Gyan E, Sanna A, Ali NH, Hobson S, Eclache V, List A, Fenaux P, Ades L
Institution:Service d'hematologie clinique, Hopital Saint-Louis, Paris, France; Groupe Francophone des Myelodysplasies, Paris, France. Electronic address:; Malignant Hematology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, United States.; Leukemia Program, Hematologic Oncology and Blood Disorders, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, United States.; Groupe Francophone des Myelodysplasies, Paris, France; Service d'hematologie clinique, Institut Paoli Calmettes, Marseille, France.; Groupe Francophone des Myelodysplasies, Paris, France; Nice cote Azur Univeristy, Nice Sophia Antipolis University, CHU of Nice, INSERM U1065, Mediterranean Center of Molecular Medicine, Nice, France.
Journal:Leuk Res. 2017 Dec;63:72-77. doi: 10.1016/j.leukres.2017.10.013. Epub 2017 Oct 27.

4:Relationship between lenalidomide dose modification, duration of therapy, and long-term outcomes in patients with myelodysplastic syndromes.
Authors:DeZern AE, Binder G, Ni Q, McGuire M, Smith BD
Institution:The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, 1650 Orleans Street, CRB1 Room 3M87, Baltimore, MD 21231, USA. Electronic address: Orleans Street, CRB1 Room 3M87, Baltimore, MD 21231, USA. Electronic address:
Journal:Leuk Res. 2017 Dec;63:10-14. doi: 10.1016/j.leukres.2017.10.005. Epub 2017 Oct 18.

5:Patterns of infectious complications in acute myeloid leukemia and myelodysplastic syndromes patients treated with 10-day decitabine regimen.
Authors:Ali AM, Weisel D, Gao F, Uy GL, Cashen AF, Jacoby MA, Wartman LD, Ghobadi A, Pusic I, Romee R, Fehniger TA, Stockerl-Goldstein KE, Vij R, Oh ST, Abboud CN, Schroeder MA, Westervelt P, DiPersio JF, Welch JS
Institution:Department of Internal Medicine, Division of Oncology, Washington University, Saint Louis, Missouri.; Division of Public Health Sciences, Department of Surgery, Washington University, St. Louis, Missouri.
Journal:Cancer Med. 2017 Dec;6(12):2814-2821. doi: 10.1002/cam4.1231. Epub 2017 Oct 23.

6:Dasatinib and Azacitidine Followed by Haploidentical Stem Cell Transplant for Chronic Myeloid Leukemia with Evolving Myelodysplasia: A Case Report and Review of Treatment Options.
Authors:Lang F, Wunderle L, Pfeifer H, Schnittger S, Bug G, Ottmann OG
Institution:Department of Hematology/Oncology, Goethe University Hospital, Frankfurt am Main, Germany. Germany. Germany. Germany. Wales, United Kingdom.
Journal:Am J Case Rep. 2017 Oct 16;18:1099-1109.

7:A predictive model of response to erythropoietin stimulating agents in myelodysplastic syndrome: from the Canadian MDS patient registry.
Authors:Houston BL, Jayakar J, Wells RA, Lenis M, Zhang L, Zhu N, Leitch HA, Nevill TJ, Yee KWL, Leber B, Sabloff M, St-Hilaire E, Kumar R, Geddes M, Shamy A, Storring JM, Keating MM, Elemary M, Delage R, Mamedov A, Buckstein R
Institution:Department of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada. Toronto, Ontario, M4N 3M5, Canada. Toronto, Ontario, M4N 3M5, Canada. Columbia, Canada. Canada. Canada. Canada. Canada. Quebec-Universite Laval, Quebec City, Quebec, Canada. Toronto, Ontario, M4N 3M5, Canada. Toronto, Ontario, M4N 3M5, Canada.
Journal:Ann Hematol. 2017 Dec;96(12):2025-2029. doi: 10.1007/s00277-017-3137-0. Epub 2017 Oct 3.

8:Phase 1/2 study of the WT1 peptide cancer vaccine WT4869 in patients with myelodysplastic syndrome.
Authors:Ueda Y, Ogura M, Miyakoshi S, Suzuki T, Heike Y, Tagashira S, Tsuchiya S, Ohyashiki K, Miyazaki Y
Institution:Department of Hematology/Oncology, Kurashiki Central Hospital, Kurashiki, Japan. Japan. Gerontology, Tokyo, Japan. Shimotsuke, Japan. Hospital, Tokyo, Japan.
Journal:Cancer Sci. 2017 Dec;108(12):2445-2453. doi: 10.1111/cas.13409. Epub 2017 Oct 25.

9:Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study.
Authors:Platzbecker U, Germing U, Gotze KS, Kiewe P, Mayer K, Chromik J, Radsak M, Wolff T, Zhang X, Laadem A, Sherman ML, Attie KM, Giagounidis A
Institution:Universitatsklinikum "Carl Gustav Carus" der Technischen Universitat Dresden, Dresden, Germany. Electronic address: Dusseldorf, Dusseldorf, Germany. Germany.
Journal:Lancet Oncol. 2017 Oct;18(10):1338-1347. doi: 10.1016/S1470-2045(17)30615-0. Epub 2017 Sep 1.

10:Phase 1 dose escalation multicenter trial of pracinostat alone and in combination with azacitidine in patients with advanced hematologic malignancies.
Authors:Abaza YM, Kadia TM, Jabbour EJ, Konopleva MY, Borthakur G, Ferrajoli A, Estrov Z, Wierda WG, Alfonso A, Chong TH, Chuah C, Koh LP, Goh BC, Chang JE, Durkes DE, Foudray MC, Kantarjian HM, Dong XQ, Garcia-Manero G
Institution:Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas. Houston, Texas. Houston, Texas. Houston, Texas. Houston, Texas. Houston, Texas. Houston, Texas. Houston, Texas. Houston, Texas. Graduate Medical School Singapore, Singapore General Hospital, Singapore. National University Hospital, Singapore. National University Hospital, Singapore. Comprehensive Cancer Center, Madison, Wisconsin. Houston, Texas. Houston, Texas. Houston, Texas. Houston, Texas.
Journal:Cancer. 2017 Dec 15;123(24):4851-4859. doi: 10.1002/cncr.30949. Epub 2017 Aug 25.

11:Cytogenetic clonal evolution in myelodysplastic syndromes is associated with inferior prognosis.
Authors:Neukirchen J, Lauseker M, Hildebrandt B, Nolting AC, Kaivers J, Kobbe G, Gattermann N, Haas R, Germing U
Institution:Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine University, Dusseldorf, Germany.; Institute for Medical Information Sciences, Biometry and Epidemiology, Ludwig-Maximilians University, Munich, Germany.; Department of Human Genetics, Heinrich-Heine University, Dusseldorf, Germany.
Journal:Cancer. 2017 Dec 1;123(23):4608-4616. doi: 10.1002/cncr.30917. Epub 2017 Jul 26.

12:Overall survival in lower IPSS risk MDS by receipt of iron chelation therapy, adjusting for patient-related factors and measuring from time of first red blood cell transfusion dependence: an MDS-CAN analysis.
Authors:Leitch HA, Parmar A, Wells RA, Chodirker L, Zhu N, Nevill TJ, Yee KWL, Leber B, Keating MM, Sabloff M, St Hilaire E, Kumar R, Delage R, Geddes M, Storring JM, Kew A, Shamy A, Elemary M, Lenis M, Mamedov A, Ivo J, Francis J, Zhang L, Buckstein R
Institution:Hematology, St. Paul's Hospital and the University of British Columbia, Vancouver, BC, Canada. Canada. Quebec, QC, Canada.
Journal:Br J Haematol. 2017 Oct;179(1):83-97. doi: 10.1111/bjh.14825. Epub 2017 Jul 5.

13:A phase 1b/2b multicenter study of oral panobinostat plus azacitidine in adults with MDS, CMML or AML with 30% blasts.
Authors:Garcia-Manero G, Sekeres MA, Egyed M, Breccia M, Graux C, Cavenagh JD, Salman H, Illes A, Fenaux P, DeAngelo DJ, Stauder R, Yee K, Zhu N, Lee JH, Valcarcel D, MacWhannell A, Borbenyi Z, Gazi L, Acharyya S, Ide S, Marker M, Ottmann OG
Institution:The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Journal:Leukemia. 2017 Dec;31(12):2799-2806. doi: 10.1038/leu.2017.159. Epub 2017 May 26.

For a FREE PREVIEW of the Medifocus Guidebook on Myelodysplastic Syndromes click here

To purchase a copy of the COMPLETE Medifocus Guidebook on Myelodysplastic Syndromes click here

To subscribe to additional FREE Medifocus Digest Alert on other disease/condition areas click here

Get the Medifocus Guidebook on Myelodysplastic Syndromes...
at a Special 20% Discount

Medifocus Guidebook on Myelodysplastic Syndromes

Updated: January 10, 2018
178 Pages

This one of a kind Guidebook offers:

  • Answers to your critical health questions including the latest treatments, clinical trials, and expert research.
  • High Quality, Professional level information you can trust and understand culled from the latest peer-reviewed journals.
  • Timely, up to date content with free guidebook updates for 1 year.
  • A unique resource to find leading experts, institutions, and support organizations including contact information and hyperlinks.
  • Over 130,000 Guidebooks Sold
  • 100% Risk Free Money Back Guarantee


The Medifocus Guidebook on Myelodysplastic Syndromes is available in the following two convenient formats:


Soft-cover book that is available for immediate shipping via either U.S. Priority Mail or International AirMail (outside the U.S.).

  • Regular List Price = $36.95
  • Less 20% Discount = - $7.40
  • Discounted Price = $29.55(excluding shipping & handling)

Order the Printed Guidebook


Available for immediate download as a PDF document.

  • Regular List Price = $27.95
  • Less 20% Discount = - $5.60
  • Discounted Price = $22.35

Order the Digital Guidebook

Order by Phone

Call Toll Free in the U.S.

From Outside the U.S.

You can also receive a 20% discount when you order your Guidebook by phone.

To receive your 20% discount, simply mention the Discount Coupon Code below to the customer service representative taking your order.

Discount Coupon Code for
Phone Orders


Coupon Expires: April 17, 2018

What Our Customers Are Saying...

"I purchased the MediFocus Guidebook on Myelodysplastic Syndromes to help my father understand the disease that he has. Doctors in France do not communicate very well the various treatment options neither do they tell you about the prognosis with enough clarity and confidence. We live in France and we believe there is no equivalent in Europe to the service you offer. We have read the Guidebook attentively and have learned a great deal about this condition. The wording is simple enough to be understandable even for non-native English speakers. It was money well spent!"
Saint Ismier, France

"Your MediFocus Guidebook on Myelodysplastic Syndromes has been a valuable companion in providing wise counsel to a beleaguered soul. Many times I was comforted by knowing that I could have my questions answered correctly and completely by using your Guidebook. I wouldn't be without it for anything. Thank you again and again."
Rockville, Maryland

"Your Medifocus Guidebook on Myelodysplastic Syndromes has been extremely valuable to me in understanding the complicated disease that afflicts me. It can be very depressing but to understand it intellectually can be very calming and heartening. Fear of the unknown is most devastating and your Guidebook provides the facts in an understandable way without 'watering-down' the science. Thank you for your outstanding publication."
Los Angeles, California

Medifocus Digest Alert is published monthly by Medifocus, Inc.
6810 Park Heights Avenue, Suite C5, Baltimore, MD 21215 USA
Copyright © 2013 Medifocus, Inc. All rights reserved.